Sophie Trouillet-Assant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophie Trouillet-Assant has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Antonin Bal
CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France
16 shared publications Karen Brengel-Pesce
15 shared publicationsBruno Pozzetto
CIRI - Centre International de Recherche en Infectiologie, University Lyon, Université Claude Bernard Lyon1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Lyon, France
14 shared publicationsAntonin Bal
12 shared publicationsBruno Lina
CIRI - Centre International de Recherche en Infectiologie, University Lyon, Université Claude Bernard Lyon1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Lyon, France
12 shared publications- Bruno Lina
HCL and CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL Lyon 1 Lyon France
12 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in EBioMedicine
- Vol. 133
Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19
- 12 October 2026
- Published by Elsevier in EBioMedicine
- Vol. 133
Open AccessSustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19
- Open Access
- 26 September 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (10)
Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
Background: Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO). Methods: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti‐aquaporin‐4 antibodies [AQP4‐NMOSD], 28 double‐seronegative NMOSD [DN‐NMOSD], 61 myelin oligodendrocyte glycoprotein antibody–associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing–remitting MS [RRMS], and 162 primary progressive MS [PPMS]). The association between log[sNFL] and log[sGFAP] and age, sex, time since relapse, EDSS, oligoclonal bands, and MRI characteristics was analyzed by multiple linear regression. The diagnostic performance of sNfL and sGFAP in discriminating between NMOSD and MS subgroups was evaluated using multivariable logistic regression and area under the curve (AUC). Results: For each group, specific associations of sNFL and sGFAP levels with patient characteristics were observed. Clearest associations were observed in AQP4‐NMOSD patients. After a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4‐NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4‐NMOSD and DN‐NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4‐NMOSD from all other groups (AUC = 0.950 [0.918;0.987]). Diagnostic probability heatmaps based on sGFAP and age illustrate the probability of each diagnosis relative to others for bedside interpretation. Conclusion: After an acute attack of NMOSD, risk score based on sGFAP and age may guide the management of patients before autoantibody status is available.
- 26 September 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (10)
Open AccessSerum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
Background: Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO). Methods: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti‐aquaporin‐4 antibodies [AQP4‐NMOSD], 28 double‐seronegative NMOSD [DN‐NMOSD], 61 myelin oligodendrocyte glycoprotein antibody–associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing–remitting MS [RRMS], and 162 primary progressive MS [PPMS]). The association between log[sNFL] and log[sGFAP] and age, sex, time since relapse, EDSS, oligoclonal bands, and MRI characteristics was analyzed by multiple linear regression. The diagnostic performance of sNfL and sGFAP in discriminating between NMOSD and MS subgroups was evaluated using multivariable logistic regression and area under the curve (AUC). Results: For each group, specific associations of sNFL and sGFAP levels with patient characteristics were observed. Clearest associations were observed in AQP4‐NMOSD patients. After a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4‐NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4‐NMOSD and DN‐NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4‐NMOSD from all other groups (AUC = 0.950 [0.918;0.987]). Diagnostic probability heatmaps based on sGFAP and age illustrate the probability of each diagnosis relative to others for bedside interpretation. Conclusion: After an acute attack of NMOSD, risk score based on sGFAP and age may guide the management of patients before autoantibody status is available.
- 4 September 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (5) , 1435-1438
Neutralizing autoantibodies against IL-1Ra in severe bacterial community-acquired pneumonia
- 4 September 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (5) , 1435-1438
Neutralizing autoantibodies against IL-1Ra in severe bacterial community-acquired pneumonia
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eaec6027
Complement augments antibody neutralization of SARS-CoV-2 variants
The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals ( n = 14), vaccinated individuals ( n = 15), and individuals with hybrid immunity ( n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.
- 22 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (859) , eaec6027
Complement augments antibody neutralization of SARS-CoV-2 variants
The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals ( n = 14), vaccinated individuals ( n = 15), and individuals with hybrid immunity ( n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.
- Open Access
Temperature-Dependent Replication and Sensitivity to Innate Immunity of Human Coronavirus HKU1
The human coronavirus HKU1, causing common colds and occasionally severe illness, remains largely uncharacterized because it has not been successfully grown on immortalized cells. Here, we identified Caco2 cells overexpressing TMPRSS2, the HKU1 receptor, as being highly permissive to infection. HKU1 replicated efficiently, formed syncytia and released infectious progeny in these cells at 33°C, the temperature of the nasal cavity, but was attenuated at 37°C. Viral entry occurred similarly at both temperatures, but subsequent viral RNA synthesis was enhanced at 33°C. Released virions displayed higher stability at 33°C. In Caco2 and primary epithelial nasal cells, HKU1 was sensitive to interferons (IFN), but induction of IFN stimulated genes, such as IFN-Induced Transmembrane Proteins (IFITMs), was delayed at 33°C. Once expressed, IFITMs comparably inhibited HKU1 fusion at both temperatures. In contrast, SARS-CoV-2 robustly replicated at 37°C. Thus, cellular permissiveness, innate immunity and viral properties collectively explain why HKU1 replicates more efficiently at nasal temperature. Our results highlight temperature-sensitivity disparities between coronaviruses, likely associated to different pathogenic outcomes.
Open AccessTemperature-Dependent Replication and Sensitivity to Innate Immunity of Human Coronavirus HKU1
The human coronavirus HKU1, causing common colds and occasionally severe illness, remains largely uncharacterized because it has not been successfully grown on immortalized cells. Here, we identified Caco2 cells overexpressing TMPRSS2, the HKU1 receptor, as being highly permissive to infection. HKU1 replicated efficiently, formed syncytia and released infectious progeny in these cells at 33°C, the temperature of the nasal cavity, but was attenuated at 37°C. Viral entry occurred similarly at both temperatures, but subsequent viral RNA synthesis was enhanced at 33°C. Released virions displayed higher stability at 33°C. In Caco2 and primary epithelial nasal cells, HKU1 was sensitive to interferons (IFN), but induction of IFN stimulated genes, such as IFN-Induced Transmembrane Proteins (IFITMs), was delayed at 33°C. Once expressed, IFITMs comparably inhibited HKU1 fusion at both temperatures. In contrast, SARS-CoV-2 robustly replicated at 37°C. Thus, cellular permissiveness, innate immunity and viral properties collectively explain why HKU1 replicates more efficiently at nasal temperature. Our results highlight temperature-sensitivity disparities between coronaviruses, likely associated to different pathogenic outcomes.
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Physiopathologie des infections ostéo-articulaires à Staphylococcus aureus
Les infections ostéo-auriculaires (IOA), principalement causées par les staphylocoques, sont des infections graves, responsables d'un taux élevé de mortalité et de morbidité suite à l'inflammation et l'importante destruction osseuse. Nous avons étudié si les interactions hôtes-pathogènes pouvaient influer sur la présentation clinique (aiguë, chronique…) des IOA. Nous avons d'abord développé un modèle in vitro d'infection intracellulaire d'ostéoblastes humains permettant de quantifier l'adhésion, l'invasion, la survie intracellulaire des staphylocoques et les dommages subis par les cellules infectées. Grâce à ce modèle, nous avons ensuite montré que les souches de S. aureus (SA) communautaires résistants à la méticilline (CA-MRSA), un groupe polyphylétique de souches hypervirulents associées à des formes aiguës et sévères d'IOA, induisent une cytotoxicité supérieure à celle des MRSA hospitaliers (HA-MRSA) associés à des IOA plus souvent chroniques. Ces résultats nous ont amené à décrire un nouveau mécanisme de virulence des CA-MRSA basé sur l'invasion des ostéoblastes et l'activité intracellulaire d'une toxine staphylococcique, les phénol-soluble modulins (PSM). Par la suite, en utilisant une large collection de souches cliniques de SA sensibles à la méticilline (MMSA) de fond génétique très divers, et en utilisant comme seul critère de corrélation la durée d'évolution réellement observée chez les patients, nous avons obtenu les premiers résultats validant l'hypothèse du rôle de l'internalisation de S. aureus dans les ostéoblastes dans la chronicité des IOA. Ces travaux nous ont également permis de démontrer la corrélation entre la dysfonction d'un des principaux systèmes de régulation de la virulence chez SA, le système agr, et le caractère chronique des IOA. La fonctionnalité du système agr, qui se traduit par la secrétion de la delta-hémolysine, est facilement détectable par spectrométrie de masse par la nouvelle technologie MALDI-TOF-MS, utilisée en laboratoire de routine pour l'identification bactérienne. Ainsi, nos résultats suggèrent que cette technique pourrait représenter la première méthode objective d'évaluation du degré de chronicité d'une IOA au moment du diagnostic, permettant ainsi d'améliorer la prise en charge initiale des patients. En parallèle, nous avons démontré que l'interaction entre SA et les ostéoclastes, seules cellules capables de résorber la matrice osseuse, était responsable de la destruction osseuse observée chez les patients atteints d'IOA par deux mécanismes complémentaires : i) SA inhibe l'ostéoclastogenèse des précurseurs myéloïdes qui se différencient alors en macrophages. Ces macrophages secrètent une multitude de signaux pro-inflammatoires facilitant ainsi le recrutement d'ostéoclastes matures sur le site de l'infection et l'ostéoclastogenèse des précurseurs non infectés ; ii) l'infection des ostéoclastes matures par SA triplent leur capacité de résorption. Ainsi nous avons démontré que les ostéoclastes jouaient un rôle central de la destruction osseuse observée lors des IOA. Nos travaux ouvrent de nouvelles perspectives dans la compréhension et l'amélioration de la prise en charge des IOA à SA
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Physiopathologie des infections ostéo-articulaires à Staphylococcus aureus
Les infections ostéo-auriculaires (IOA), principalement causées par les staphylocoques, sont des infections graves, responsables d'un taux élevé de mortalité et de morbidité suite à l'inflammation et l'importante destruction osseuse. Nous avons étudié si les interactions hôtes-pathogènes pouvaient influer sur la présentation clinique (aiguë, chronique…) des IOA. Nous avons d'abord développé un modèle in vitro d'infection intracellulaire d'ostéoblastes humains permettant de quantifier l'adhésion, l'invasion, la survie intracellulaire des staphylocoques et les dommages subis par les cellules infectées. Grâce à ce modèle, nous avons ensuite montré que les souches de S. aureus (SA) communautaires résistants à la méticilline (CA-MRSA), un groupe polyphylétique de souches hypervirulents associées à des formes aiguës et sévères d'IOA, induisent une cytotoxicité supérieure à celle des MRSA hospitaliers (HA-MRSA) associés à des IOA plus souvent chroniques. Ces résultats nous ont amené à décrire un nouveau mécanisme de virulence des CA-MRSA basé sur l'invasion des ostéoblastes et l'activité intracellulaire d'une toxine staphylococcique, les phénol-soluble modulins (PSM). Par la suite, en utilisant une large collection de souches cliniques de SA sensibles à la méticilline (MMSA) de fond génétique très divers, et en utilisant comme seul critère de corrélation la durée d'évolution réellement observée chez les patients, nous avons obtenu les premiers résultats validant l'hypothèse du rôle de l'internalisation de S. aureus dans les ostéoblastes dans la chronicité des IOA. Ces travaux nous ont également permis de démontrer la corrélation entre la dysfonction d'un des principaux systèmes de régulation de la virulence chez SA, le système agr, et le caractère chronique des IOA. La fonctionnalité du système agr, qui se traduit par la secrétion de la delta-hémolysine, est facilement détectable par spectrométrie de masse par la nouvelle technologie MALDI-TOF-MS, utilisée en laboratoire de routine pour l'identification bactérienne. Ainsi, nos résultats suggèrent que cette technique pourrait représenter la première méthode objective d'évaluation du degré de chronicité d'une IOA au moment du diagnostic, permettant ainsi d'améliorer la prise en charge initiale des patients. En parallèle, nous avons démontré que l'interaction entre SA et les ostéoclastes, seules cellules capables de résorber la matrice osseuse, était responsable de la destruction osseuse observée chez les patients atteints d'IOA par deux mécanismes complémentaires : i) SA inhibe l'ostéoclastogenèse des précurseurs myéloïdes qui se différencient alors en macrophages. Ces macrophages secrètent une multitude de signaux pro-inflammatoires facilitant ainsi le recrutement d'ostéoclastes matures sur le site de l'infection et l'ostéoclastogenèse des précurseurs non infectés ; ii) l'infection des ostéoclastes matures par SA triplent leur capacité de résorption. Ainsi nous avons démontré que les ostéoclastes jouaient un rôle central de la destruction osseuse observée lors des IOA. Nos travaux ouvrent de nouvelles perspectives dans la compréhension et l'amélioration de la prise en charge des IOA à SA
- Open Access
Functional alterations of immune gene expression in ICU and non-ICU patients with Legionnaires’ disease, a prospective observational study
Legionnaires’ disease (LD), a pneumonia caused by Legionella pneumophila intracellular bacterium, leads to intensive care unit (ICU) admission in 20-40% of cases. While these ICU-LD patients display severe lung injury or septic shock, their functional immune response remains poorly understood. The present study aimed, through a large immune gene expression assessment, to improve the understanding of immune cell functionality after whole blood LPS ex vivo stimulation in ICU-LD patients compared with non-ICU. Both ICU and non-ICU-LD displayed altered gene expression indicating that both patients’ immune cells are less able to respond to the LPS ex vivo stimulus than a healthy population. ICU-LD patients had 1.6-fold greater number of less-expressed genes (35/93 vs 22/93, p=0.039), and lower Log2(FC) of these genes (median [IQR]: -1.9 [-2.6;-1.5] vs -1.2 [-1.7;-0.9], p=0.0011) than non-ICU-LD. Seven genes were significantly less expressed by ICU-LD patients ( IRF7 , MX1 , NFKBI2 , NFKBIA , RELB , SRC , TIM3 ; p-value range: 0.029-0.0080). Top five gene ontology biological processes, subcellular localisations, and reactome pathways (STRING database) uniquely enriched in ICU-LD-patients and related less-expressed genes were cellular response to LPS ( CCL2 , NFKBIA , IRAK2 , TIM3, SRC , NFKB1 ), regulation of IFN-β production ( IRF7 , RIG1 , OAS2 , RELB ), I-κB/NF-κB complex ( NFKBIA , NFKB1 , NFKB2 ), IFN regulatory factor complex ( RIG1 , IRF7 ), and TRAF6-mediated NF-κB activation pathway ( NFKBIA , NFKB1 , NFKB2 , RIG1 ). Immune gene expression alterations in LD after LPS stimulation were found herein, with more pronounced alterations in ICU-LD patients. A reduced expression of key genes and pathways involved in controlling Legionella proliferation in ICU-LD patients may contribute to increased disease severity.
Open AccessFunctional alterations of immune gene expression in ICU and non-ICU patients with Legionnaires’ disease, a prospective observational study
Legionnaires’ disease (LD), a pneumonia caused by Legionella pneumophila intracellular bacterium, leads to intensive care unit (ICU) admission in 20-40% of cases. While these ICU-LD patients display severe lung injury or septic shock, their functional immune response remains poorly understood. The present study aimed, through a large immune gene expression assessment, to improve the understanding of immune cell functionality after whole blood LPS ex vivo stimulation in ICU-LD patients compared with non-ICU. Both ICU and non-ICU-LD displayed altered gene expression indicating that both patients’ immune cells are less able to respond to the LPS ex vivo stimulus than a healthy population. ICU-LD patients had 1.6-fold greater number of less-expressed genes (35/93 vs 22/93, p=0.039), and lower Log2(FC) of these genes (median [IQR]: -1.9 [-2.6;-1.5] vs -1.2 [-1.7;-0.9], p=0.0011) than non-ICU-LD. Seven genes were significantly less expressed by ICU-LD patients ( IRF7 , MX1 , NFKBI2 , NFKBIA , RELB , SRC , TIM3 ; p-value range: 0.029-0.0080). Top five gene ontology biological processes, subcellular localisations, and reactome pathways (STRING database) uniquely enriched in ICU-LD-patients and related less-expressed genes were cellular response to LPS ( CCL2 , NFKBIA , IRAK2 , TIM3, SRC , NFKB1 ), regulation of IFN-β production ( IRF7 , RIG1 , OAS2 , RELB ), I-κB/NF-κB complex ( NFKBIA , NFKB1 , NFKB2 ), IFN regulatory factor complex ( RIG1 , IRF7 ), and TRAF6-mediated NF-κB activation pathway ( NFKBIA , NFKB1 , NFKB2 , RIG1 ). Immune gene expression alterations in LD after LPS stimulation were found herein, with more pronounced alterations in ICU-LD patients. A reduced expression of key genes and pathways involved in controlling Legionella proliferation in ICU-LD patients may contribute to increased disease severity.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200498
Serum Neurofilament Light Chain Correlates With Clinical Severity and Predicts Mortality in Anti-IgLON5 Disease
Anti-IgLON5 disease manifests by various neurologic symptoms, the severity of which can be evaluated using the anti-IgLON5 composite score (ICS). This study assessed the correlation of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) with the ICS and investigated these biomarkers as predictors of long-term clinical severity and mortality in anti-IgLON5 disease. Patients diagnosed with anti-IgLON5 disease at a national reference center (2016-2024) with available serum and CSF samples were included. NfL and GFAP concentrations were measured in these samples using Simoa assay Neurology 2-Plex B Kit. The severity of symptoms was classified according to the ICS, which was retrospectively evaluated at diagnosis, at last clinical evaluation, and at any other timepoint when samples were collected. Thirty patients (60% male, median age 72 years) were included. Serum NfL concentration was significantly correlated with the total ICS (rho = 0.38, p = 0.025) and its partial bulbar score (rho = 0.39, p = 0.020); serum GFAP concentration was significantly correlated only with the bulbar ICS (rho = 0.34, p = 0.044). CSF NfL and GFAP concentrations were not significantly correlated with the total ICS nor any of its partial scores. Anti-IgLON5 antibody CSF titers, but not serum titers, showed a significant inverse correlation with the total ICS (rho = -0.44, p = 0.04). In 26 patients sampled p = 0.007). In patients with bulbar involvement (n = 22), serum NfL concentration was lower than in 10 controls with bulbar amyotrophic lateral sclerosis (median interquartile range [IQR] 26 pg/mL [21-51] vs 158 pg/mL [100-340], p < 0.001) and higher than in 10 controls with bulbar myasthenia gravis (median [IQR] 15 pg/mL [8-26], p = 0.040). In anti-IgLON5 disease, serum NfL and GFAP are elevated and correlate with the clinical severity, especially of bulbar symptoms. In clinical practice, serum NfL could be useful for disease monitoring and to predict the risk of death.
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200498
Open AccessSerum Neurofilament Light Chain Correlates With Clinical Severity and Predicts Mortality in Anti-IgLON5 Disease
Anti-IgLON5 disease manifests by various neurologic symptoms, the severity of which can be evaluated using the anti-IgLON5 composite score (ICS). This study assessed the correlation of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) with the ICS and investigated these biomarkers as predictors of long-term clinical severity and mortality in anti-IgLON5 disease. Patients diagnosed with anti-IgLON5 disease at a national reference center (2016-2024) with available serum and CSF samples were included. NfL and GFAP concentrations were measured in these samples using Simoa assay Neurology 2-Plex B Kit. The severity of symptoms was classified according to the ICS, which was retrospectively evaluated at diagnosis, at last clinical evaluation, and at any other timepoint when samples were collected. Thirty patients (60% male, median age 72 years) were included. Serum NfL concentration was significantly correlated with the total ICS (rho = 0.38, p = 0.025) and its partial bulbar score (rho = 0.39, p = 0.020); serum GFAP concentration was significantly correlated only with the bulbar ICS (rho = 0.34, p = 0.044). CSF NfL and GFAP concentrations were not significantly correlated with the total ICS nor any of its partial scores. Anti-IgLON5 antibody CSF titers, but not serum titers, showed a significant inverse correlation with the total ICS (rho = -0.44, p = 0.04). In 26 patients sampled p = 0.007). In patients with bulbar involvement (n = 22), serum NfL concentration was lower than in 10 controls with bulbar amyotrophic lateral sclerosis (median interquartile range [IQR] 26 pg/mL [21-51] vs 158 pg/mL [100-340], p < 0.001) and higher than in 10 controls with bulbar myasthenia gravis (median [IQR] 15 pg/mL [8-26], p = 0.040). In anti-IgLON5 disease, serum NfL and GFAP are elevated and correlate with the clinical severity, especially of bulbar symptoms. In clinical practice, serum NfL could be useful for disease monitoring and to predict the risk of death.
- Open Access
- 24 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Case-based evidence links increased SARS-CoV-2 diversity to impaired IFN-I response in severe COVID-19
Severe COVID-19 with neutralizing anti–type I interferon autoantibodies correlates with high intra-host SARS-CoV-2 diversity. Findings suggest that impaired interferon-mediated viral control may facilitate the emergence of viral variants within individual patients during prolonged infection.
- 24 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Open AccessCase-based evidence links increased SARS-CoV-2 diversity to impaired IFN-I response in severe COVID-19
Severe COVID-19 with neutralizing anti–type I interferon autoantibodies correlates with high intra-host SARS-CoV-2 diversity. Findings suggest that impaired interferon-mediated viral control may facilitate the emergence of viral variants within individual patients during prolonged infection.